Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Semaglutide is FDA-approved for chronic (long-term) use
RAND, a not-for-profit and bipartisan research group, conducted the poll
Our Ozempic Lawyers are currently accepting new clients for this case
For a broader comparison between the two major GLP-1 medications, see our semaglutide versus tirzepatide comparison
In a phase 3, double-blind, randomized, controlled trial, 2,539 adults with a body-mass index (BMI) of 30 or greater, or 27 or greater with at least one weight-related complication, were given weekly subcutaneous injections of tirzepatide (5 mg, 10 mg, or 15 mg) or a placebo for 72 weeks
